Wendy Gidman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wendy Gidman has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Deborah P. M. Symmons
Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
1 shared publication - Rachel Meacock
Division of Population Health, Health Services Research & Primary Care, University of Manchester, Manchester, United Kingdom
1 shared publication Ross Coomber
Drug and Alcohol Research Unit, School of Social Science and Social Work, Plymouth University, 9 Portland Villas, Plymouth, Devon PL4 8AA, UK
1 shared publication
Latest Publications
- 15 April 2015
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 17 (5) , 1-13
The Humanistic and Economic Burden of Juvenile Idiopathic Arthritis in the era of Biologic Medication
Juvenile idiopathic arthritis (JIA) is a poorly understood, heterogeneous, incurable, inflammatory syndrome. Long-term outcomes are uncertain, and this painful condition can result in lifelong disability. JIA is associated with considerable financial and humanistic burden for those affected and the healthcare system. Early diagnosis and effective treatment are indicated to optimise outcomes. Modern treatment aims to achieve remission and preserve joint function by using disease-modifying antirheumatic drugs (DMARDs) early. DMARDs can be classified as conventional/traditional or biologic. Biologic medications may be more effective but cost approximately ten times more than traditional DMARDs. Decision-makers in healthcare are increasingly comparing the cost and consequences of alternative treatment strategies to guide resource allocation decisions. There have been few economic evaluations to date to guide medicines optimisation in JIA. This systematic review highlights the lack of existing evidence relating to the humanistic and economic burden of JIA in the era of biologic medication.
- 15 April 2015
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 17 (5) , 1-13
The Humanistic and Economic Burden of Juvenile Idiopathic Arthritis in the era of Biologic Medication
Juvenile idiopathic arthritis (JIA) is a poorly understood, heterogeneous, incurable, inflammatory syndrome. Long-term outcomes are uncertain, and this painful condition can result in lifelong disability. JIA is associated with considerable financial and humanistic burden for those affected and the healthcare system. Early diagnosis and effective treatment are indicated to optimise outcomes. Modern treatment aims to achieve remission and preserve joint function by using disease-modifying antirheumatic drugs (DMARDs) early. DMARDs can be classified as conventional/traditional or biologic. Biologic medications may be more effective but cost approximately ten times more than traditional DMARDs. Decision-makers in healthcare are increasingly comparing the cost and consequences of alternative treatment strategies to guide resource allocation decisions. There have been few economic evaluations to date to guide medicines optimisation in JIA. This systematic review highlights the lack of existing evidence relating to the humanistic and economic burden of JIA in the era of biologic medication.
- 1 May 2014
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 10 (3) , 576-587
Contested space in the pharmacy: Public attitudes to pharmacy harm reduction services in the West of Scotland
- 1 May 2014
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 10 (3) , 576-587
Contested space in the pharmacy: Public attitudes to pharmacy harm reduction services in the West of Scotland